Generic Medicine Info
Known or suspected genetic susceptibility to malignant hyperthermia (e.g. presence of RYR1 or CACNA1S pathogenic variants); seizure disorders, head trauma, pre-existing increased intracranial pressure or mass; liver disease (e.g. biliary tract disease, jaundice, hepatic damage) after previous enflurane or other inhalational anaesthetic use.
Special Precautions
Patient with cardiac disease or with risk factors for QT prolongation (e.g. hypertension, congenital long QT syndrome, heart failure, MI, bradycardia, cardiac arrhythmias, coronary artery disease, hypomagnesaemia, hypokalaemia, hypocalcaemia, diabetes mellitus, thyroid disease, malnutrition, alcoholism); neuromuscular disease (e.g. Duchenne muscular dystrophy), myasthenia gravis, more susceptible to cortical stimulation. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may impair your mental cognition for some time after administration, if affected, do not drive or operate machinery. Monitoring Parameters Monitor arterial blood gases (ABGs), urine flow; blood pressure, heart rate, serum electrolytes, and ECG periodically in patients taking QT-prolonging agents.
Adverse Reactions
Significant: QT prolongation with risk of ventricular tachycardia and torsade de pointes, uterine relaxation (high concentration), post-anaesthesia emergence delirium or agitation. Rarely, hepatotoxicity (e.g. jaundice, hepatic necrosis or failure). Blood and lymphatic system disorders: Leukocytosis. Cardiac disorders: Arrhythmia. Gastrointestinal disorders: Nausea, vomiting, hypersalivation. Investigations: Elevated WBC count and serum fluoride concentrations; increased serum transaminase. Musculoskeletal and connective tissue disorders: Shivering. Nervous system disorders: Convulsions (high concentration). Respiratory, thoracic and mediastinal disorders: Hypoxia, bronchospasm, respiratory depression. Vascular disorders: Hypotension.
Potentially Fatal: Rarely, malignant hyperthermia and perioperative hyperkalaemia resulting in cardiac arrhythmias (children).
Drug Interactions
May increase the risk of perioperative hyperkalaemia with succinylcholine. May produce ventricular arrhythmias or hypertension with epinephrine. May increase the risk of QT prolongation with agents that cause electrolyte imbalance or those known to prolong QT interval. May enhance the effects of competitive neuromuscular blockers (e.g. atracurium). May increase the metabolism and risk of hepatotoxicity with isoniazid. May enhance hypotensive effects with MAOIs. May cause carboxyhaemoglobinaemia with desiccated CO2 absorbents in anaesthetic circle breathing systems.
ATC Classification
N01AB04 - enflurane ; Belongs to the class of halogenated hydrocarbons. Used as general anesthetics.
Disclaimer: This information is independently developed by CIMS based on enflurane from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in